Summary
The p27Kip1 gene has been identified as inductor of cell cycle arrest at the G1 checkpoint to prevent entry of somatic cells into the S phase of the cell cycle when substantial DNA damage has occurred. It has been suggested that decreased expression of the p27Kip1 protein may contribute to the development of human malignancies due to loss of critical antiproliferative mechanisms. In the present study, 95 specimens (T1–T4) from 95 randomly selected patients undergoing radical prostatectomy at the Urological Department of Hannover University (82 patients) as well as in the Josef Hospital Regensburg (13 patients) between 1981 and 1992 for whom tissue blocks for immunohistochemical investigation were available, were investigated for different biological and clinical characteristics as possible predictors for recurrence-free and long-term survival: age, depth of tumour infiltration, histological grade, lymph node status, as well as decreased expression of the p27Kip1 protein. After a median follow-up up of 56 months (24–151 months), seven of 21 (33%) patients (Group 1) with loss of p27Kip1 protein expression or a relative amount of <10% of positively stained tumour cells developed recurrent disease in contrast to 17 of 74 (23%) patients (Group 2) with retained p27Kip1 protein expression (≥10% of positively stained tumour cells). The median recurrence-free survival was 14 months (5–40 months) for patients from Group 1 and 31 months (7–133 months) for Group 2 patients (P = 0.02). In multivariate analysis, loss of p27Kip1 protein expression was identified as the only independent prognostic parameter for recurrence-free survival. In contrast, neither the univariate nor the multivariate analysis showed a correlation between loss of p27Kip1 protein expression and the long-term survival of the patients. Prospective studies are urgently needed to confirm the independent prognostic value of decreased p27Kip1 protein expression together with overexpression of the p53 tumour suppressor protein in patients with localized prostate cancer. The availability of more refined prognostically important biological variables in addition to established prognostic factors like tumour stage or Gleason score might help decision making in patients at high risk for the development of local recurrence or systemic tumour progression.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ackerman, DA, Barry, JM, Wicklund, RA, Olson, N & Lowe, BA (1993). Analysis of high risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 150: 1845–1850.
Adolfsson, J, Carstensen, T & Lowhagen, T (1992). Deferred treatment in localised prostate cancer. Br J Urol 69: 183–187.
Bullrich, FF, McLachlan, TK, Sang, N, Druck, T, Veronese, ML, Allen, SL, Chiorazzi, N, Koff, A, Heubner, K, Croce, CM & Giordano, A (1995). Chromosomal mapping of members of the cdk2 family of protein kinase, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res 55: 1199–1205.
Cote, R, Shi, Y, Groshen, S, Feng, A-C, Cordon-Cardo, C, Skinner, D & Lieskovsky, G (1998). Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 90: 916–920.
Craig, C, Wersto, R, Kim, M, Ohri, E, Li, Z, Katayose, D, Lee, SJ, Trepel, J, Cowan, K & Seth, P (1997). A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin–cdk activity in human breast cancer cells. Oncogene 14: 2283–2289.
Elledge, SJ (1996). Cell cycle checkpoints: preventing an identity crisis. Science 274: 1664–1672.
Esposito, V, Baldi, A, De Luca, A, Groger, AM, Loda, M, Giordano, GG, Caputi, M, Baldi, F, Pagano, M & Giordano, A (1997). Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381–3385.
Ferrando, AA, Balbin, M, Pendas, AM, Vizoso, F, Velasco, G & Lopez-Otin, C (1996). Mutational analysis of the human cyclin-dependent kinase inhibitor p27Kip1 in primary breast carcinomas. Hum Genet 97: 91–94.
Fredersdorf, S, Burns, J, Milne, AM, Packham, G, Falls, L, Gillett, CE, Royds, JA, Peston, D, Hall, PA, Hanby, AM, Barnes, DM, Shousha, S, O’ Hare, MJ & Lu, X (1997). High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380–6385.
George, NJR (1988). Natural history of localised prostate cancer managed by conservative therapy alone. Lancet i, 494–497.
Hermanek P, Sobin LH (eds.) (1992). UICC TNM Classification of Malignant Tumours, 4th edn, 2nd revision. Springer: Berlin.
Johansson, JE, Adami, HO, Andersson, SO, Bergström, R, Holmberg, L & Krusemo, UB (1992). High 10-year survival rate in patients with early untreated prostate cancer. JAMA 267: 2191–2196.
Kato, J, Matsuoka, M, Polyak, K, Massague, J & Sherr, CJ (1994). Cyclic AMP- induced G1 phase arrest mediated by an inhibitor (p27kip1) of cyclin-dependent kinase 4 activation. Cell 79: 487–496.
Kawamata, N, Seriu, T, Koeffler, HP & Bartram, CR (1996). Molecular analysis of the cyclin-dependent kinase inhibitor family: p16 (CDKN2/MTS1/INK4A), p18 (INK4C) and p27 (Kip1) genes in neuroblastomas. Cancer 77: 570–575.
Kawasaki, T, Tomita, Y, Bilim, V, Takeda, M, Takahashi, K & Kumanishi, T (1996). Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer 68: 501–505.
Kuczyk, MA, Serth, J, Bokemeyer, C, Machtens, S, Minssen, A, Bathke, W, Hartmann, J & Jonas, U (1998). The prognostic value of p53 for the long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 34: 679–686.
Lee, CCR, Yamamoto, S, Wanibuchi, H, Wada, S, Sugimura, K, Kishimoto, T & Fukushima, S (1997). Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Cancer Res 57: 4765–4776.
Martin, E, Cacheux, V, Cave, H, Lapierre, JM, Le Paslier, D & Grandchamp, B (1995). Localization of the CDKN4/p27(Kip1) gene to human chromosome 12p12.3. Hum Genet 96: 668–670.
McGarvey, TW & Malkowicz, SB (1996). The role of the cell cycle in genitourinary carcinoma. World J Urol 14: 310–317.
Nasmyth, K (1996). Viewpoint: putting the cell cycle in order. Science 274: 1643–1645.
Parker, SI, Tong, T, Bolden, S & Wingo, PA (1996). Cancer Statistics 1996. CA Cancer J Clin 46: 5–27.
Polyak, K, Kato, J, Solomon, MJ, Sherr, CJ, Massague, J, Roberts, JM & Koff, A (1994a). p27Kip1 a cyclin–cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8: 9–22.
Polyak, K, Lee, M-H, Erdjument-Bromage, H, Koff, A, Roberts, JM, Tempst, P & Massague, J (1994b). Cloning of p27(Kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59–66.
Ponce-Castaneda, MV, Lee, MH, Latres, E, Polyak, K, Lacombe, L & Montgomery, K (1995). P27 Kip1: chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res 55: 1211–1214.
Porter, PL, Malone, KE, Heagerty, PJ, Alexander, GM, Gatti, LA, Firpo, EJ, Daling, JR & Roberts, JM (1997). Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222–225.
Spirin, KS, Simpson, JF, Takeuchi, S, Kawamata, N, Miller, CW & Koeffler, HP (1996). p27/Kip1 mutation found in breast cancer. Cancer Res 56: 2400–2404.
Stamey, TA, Freiha, FS, McNeal, JE, Redwine, EA, Whitemore, AS & Schmid, HP (1993). Localized prostate cancer: relationship of tumor volume to clinical significance for the treatment of prostate cancer. Cancer 71: 933–938.
Wu, G, Fan, RS, Li, W, Ko, TC & Brattain, MG (1997). Modulation of cell cycle control by vitamin D3 and its analogue, EB 1089, in human breast cancer cells. Oncogene 15: 1555–1563.
Yang, RM, Naitoh, J, Murphy, M, Wang, HJ, Phillipson, J, De Kernion, JB, Loda, M & Reiter, RE (1998). Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941–945.
Yasui, W, Kudo, Y, Semba, S, Yokozaki, H & Tahara, E (1997). Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 88: 625–629.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kuczyk, M., Machtens, S., Hradil, K. et al. Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 81, 1052–1058 (1999). https://doi.org/10.1038/sj.bjc.6690806
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690806
Keywords
This article is cited by
-
EPMA position paper in cancer: current overview and future perspectives
EPMA Journal (2015)
-
Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer
Journal of Negative Results in BioMedicine (2012)
-
Expression of p21waf1/cip1, p27kip1, p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer
Pathology & Oncology Research (2008)
-
Expression of p27(Kip1), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells
International Urology and Nephrology (2008)
